RESUMO
Edible fungi cultivation serves as an efficient biological approach to transforming agroforestry byproducts, particularly Korshinsk peashrub (KP) branches into valuable mushroom (Lentinus edodes) products. Despite the widespread use of KP, the molecular mechanisms underlying its regulation of mushroom development remain largely unknown. In this study, we conducted a combined analysis of transcriptome and metabolism of mushroom fruiting bodies cultivated on KP substrates compared to those on apple wood sawdust (AWS) substrate. Our aim was to identify key metabolic pathways and genes that respond to the effects of KP substrates on mushrooms. The results revealed that KP induced at least a 1.5-fold increase in protein and fat content relative to AWS, with 15% increase in polysaccharide and total sugar content in mushroom fruiting bodies. There are 1196 differentially expressed genes (DEGs) between mushrooms treated with KP relative to AWS. Bioinformatic analysis show significant enrichments in amino acid metabolic process, oxidase activity, malic enzyme activity and carbon metabolism among the 698 up-regulated DEGs induced by KP against AWS. Additionally, pathways associated with organic acid transport and methane metabolism were significantly enriched among the 498 down-regulated DEGs. Metabolomic analysis identified 439 differentially abundant metabolites (DAMs) in mushrooms treated with KP compared to AWS. Consistent with the transcriptome data, KEGG analysis on metabolomic dataset suggested significant enrichments in carbon metabolism, alanine, aspartate and glutamate metabolism among the up-regulated DAMs by KP. In particular, some DAMs were enhanced by 1.5-fold, including D-glutamine, L-glutamate, glucose and pyruvate in mushroom samples treated with KP relative to AWS. Targeted metabolomic analysis confirmed the contents of DAMs related to glutamate metabolism and energy metabolism. In conclusion, our findings suggest that reprogrammed carbon metabolism and oxidoreductase pathways act critical roles in the enhanced response of mushroom to KP substrates.
Assuntos
Carbono , Transcriptoma , Carbono/metabolismo , Oxirredutases/metabolismo , Oxirredutases/genética , Redes e Vias Metabólicas , Perfilação da Expressão Gênica , Regulação Fúngica da Expressão Gênica , Agaricales/genética , Agaricales/metabolismo , Cogumelos Shiitake/metabolismo , Cogumelos Shiitake/genética , Carpóforos/metabolismo , Carpóforos/genética , Proteínas Fúngicas/metabolismo , Proteínas Fúngicas/genéticaRESUMO
Cusatuzumab is a high-affinity, anti-CD70 monoclonal antibody under investigation in acute myeloid leukemia (AML). This two-part, open-label, multicenter, phase I/II trial evaluated cusatuzumab plus azacitidine in patients with newly diagnosed AML ineligible for intensive chemotherapy. Patients received a single dose of cusatuzumab at one of four dose levels (1, 3, 10, or 20 mg/kg) 14 days before starting combination therapy. In phase I dose escalation, cusatuzumab was then administered on days 3 and 17, in combination with azacitidine (75 mg/m2) on days 1-7, every 28 days. The primary objective in phase I was to determine the recommended phase II dose (RP2D) of cusatuzumab plus azacitidine. The primary objective in phase II was efficacy at the RP2D (selected as 10 mg/kg). Thirty-eight patients were enrolled: 12 in phase I (three per dose level; four with European LeukemiaNet 2017 adverse risk) and 26 in phase II (21 with adverse risk). An objective response (≥partial remission) was achieved by 19/38 patients (including 8/26 in phase II); 14/38 achieved complete remission. Eleven patients (37.9%) achieved an objective response among the 29 patients in phase I and phase II treated at the RP2D. At a median follow-up of 10.9 months, median duration of first response was 4.5 months and median overall survival was 11.5 months. The most common treatment-emergent adverse events were infections (84.2%) and hematologic toxicities (78.9%). Seven patients (18.4%) reported infusion-related reactions, including two with grade 3 events. Thus, cusatuzumab/azacitidine appears generally well tolerated and shows preliminary efficacy in this setting. Investigation of cusatuzumab combined with current standard-of-care therapy, comprising venetoclax and azacitidine, is ongoing.
Assuntos
Antineoplásicos , Leucemia Mieloide Aguda , Humanos , Azacitidina/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Antineoplásicos/uso terapêutico , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/tratamento farmacológico , Anticorpos Monoclonais/uso terapêuticoRESUMO
OBJECTIVE: BMS-986120 is a novel first-in-class oral PAR4 (protease-activated receptor 4) antagonist with potent and selective antiplatelet effects. We sought to determine for the first time, the effect of BMS-986120 on human ex vivo thrombus formation. APPROACH AND RESULTS: Forty healthy volunteers completed a phase 1 parallel-group PROBE trial (Prospective Randomized Open-Label Blinded End Point). Ex vivo platelet activation, platelet aggregation, and thrombus formation were measured at 0, 2, and 24 hours after (1) oral BMS-986120 (60 mg) or (2) oral aspirin (600 mg) followed at 18 hours with oral aspirin (600 mg) and oral clopidogrel (600 mg). BMS-986120 demonstrated highly selective and reversible inhibition of PAR4 agonist peptide (100 µM)-stimulated P-selectin expression, platelet-monocyte aggregates, and platelet aggregation (P<0.001 for all). Compared with pretreatment, total thrombus area (µm2/mm) at high shear was reduced by 29.2% (95% confidence interval, 18.3%-38.7%; P<0.001) at 2 hours and by 21.4% (9.3%-32.0%; P=0.002) at 24 hours. Reductions in thrombus formation were driven by a decrease in platelet-rich thrombus deposition: 34.8% (19.3%-47.3%; P<0.001) at 2 hours and 23.3% (5.1%-38.0%; P=0.016) at 24 hours. In contrast to aspirin alone, or in combination with clopidogrel, BMS-986120 had no effect on thrombus formation at low shear (P=nonsignificant). BMS-986120 administration was not associated with an increase in coagulation times or serious adverse events. CONCLUSIONS: BMS-986120 is a highly selective and reversible oral PAR4 antagonist that substantially reduces platelet-rich thrombus formation under conditions of high shear stress. Our results suggest PAR4 antagonism has major potential as a therapeutic antiplatelet strategy. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02439190.
Assuntos
Benzofuranos/administração & dosagem , Plaquetas/efeitos dos fármacos , Fibrinolíticos/administração & dosagem , Imidazóis/administração & dosagem , Morfolinas/administração & dosagem , Inibidores da Agregação Plaquetária/administração & dosagem , Agregação Plaquetária/efeitos dos fármacos , Receptores de Trombina/antagonistas & inibidores , Tiazóis/administração & dosagem , Trombose/prevenção & controle , Administração Oral , Adulto , Aspirina/administração & dosagem , Benzofuranos/efeitos adversos , Benzofuranos/farmacocinética , Plaquetas/metabolismo , Clopidogrel/administração & dosagem , Feminino , Fibrinolíticos/efeitos adversos , Fibrinolíticos/farmacocinética , Voluntários Saudáveis , Humanos , Imidazóis/efeitos adversos , Imidazóis/farmacocinética , Masculino , Morfolinas/efeitos adversos , Morfolinas/farmacocinética , Inibidores da Agregação Plaquetária/efeitos adversos , Inibidores da Agregação Plaquetária/farmacocinética , Estudos Prospectivos , Receptores de Trombina/sangue , Escócia , Transdução de Sinais/efeitos dos fármacos , Tiazóis/efeitos adversos , Tiazóis/farmacocinética , Trombose/sangue , Trombose/diagnóstico , Fatores de Tempo , Resultado do Tratamento , Adulto JovemRESUMO
AIMS: The aims of the present study were to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-962212, a first-in-class factor XIa inhibitor, in Japanese and non-Japanese healthy subjects. METHODS: This was a randomized, placebo-controlled, double-blind, sequential, ascending-dose study of 2-h (part A) and 5-day (part B) intravenous (IV) infusions of BMS-962212. Part A used four doses (1.5, 4, 10 and 25 mg h-1 ) of BMS-962212 or placebo in a 6:2 ratio per dose. Part B used four doses (1, 3, 9 and 20 mg h-1 ) enrolling Japanese (n = 4 active, n = 1 placebo) and non-Japanese (n = 4 active, n = 1 placebo) subjects per dose. The PK, PD, safety and tolerability were assessed throughout the study. RESULTS: BMS-962212 was well tolerated; there were no signs of bleeding, and adverse events were mild. In parts A and B, BMS-962212 demonstrated dose proportionality. The mean half-life in parts A and B ranged from 2.04 to 4.94 h and 6.22 to 8.65 h, respectively. Exposure-dependent changes were observed in the PD parameters, activated partial thromboplastin time (aPTT) and factor XI clotting activity (FXI:C). The maximum mean aPTT and FXI:C change from baseline at 20 mg h-1 in part B was 92% and 90%, respectively. No difference was observed in weight-corrected steady-state concentrations, aPTT or FXI:C between Japanese and non-Japanese subjects (P > 0.05). CONCLUSION: BMS-962212 has tolerability, PK and PD properties suitable for investigational use as an acute antithrombotic agent in Japanese or non-Japanese subjects.
Assuntos
Isoquinolinas/efeitos adversos , Isoquinolinas/farmacologia , Isoquinolinas/farmacocinética , para-Aminobenzoatos/efeitos adversos , para-Aminobenzoatos/farmacologia , para-Aminobenzoatos/farmacocinética , Adolescente , Adulto , Povo Asiático/estatística & dados numéricos , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Fibrinolíticos/farmacologia , Voluntários Saudáveis , Humanos , Infusões Intravenosas , Isoquinolinas/administração & dosagem , Masculino , Pessoa de Meia-Idade , Tempo de Tromboplastina Parcial/estatística & dados numéricos , População Branca/estatística & dados numéricos , Adulto Jovem , para-Aminobenzoatos/administração & dosagemRESUMO
Janus kinase (JAK) signaling has been implicated in human inflammatory diseases, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Lorpucitinib (JNJ-64251330) is an oral, small molecule, pan-JAK inhibitor. Unlike systemic JAK antagonists, lorpucitinib was found to have enteric (gut)-selective properties, providing possible applications in diseases of the human gastrointestinal tract. Here, lorpucitinib was evaluated in a phase I, two-part, dosing study (NCT04552197) to assess pharmacokinetics, pharmacodynamic biomarkers, and safety in healthy participants. In part 1, 24 participants were randomized to 1 of 4 treatment arms receiving either lorpucitinib (30 mg daily, 30 mg every 12 hours (q12h), or 75 mg q12h) or tofacitinib (5 mg q12h) for 5 days. Part 2 was a food-effect study in which 12 participants received a single 75-mg dose of lorpucitinib under either fasting or fed conditions. In part 1, plasma and gut tissue concentrations of lorpucitinib showed approximately dose-proportional increases. At all doses, lorpucitinib concentrations were significantly higher (392- to 1928-fold) in the gut mucosal biopsies vs. the corresponding plasma samples, demonstrating high enteric selectivity and significantly exceeding both the tissue concentrations (> 200-fold) and tissue/plasma ratios observed with tofacitinib. JAK inhibition in biopsies was confirmed via reduction in pSTAT-3 levels. In part 2, lorpucitinib plasma concentrations were detectable but at low levels, with no statistical differences in PK parameters between the fed and fasted groups. Lorpucitinib was safe and well-tolerated, and the data may be useful in designing studies to evaluate lorpucitinib in patients with JAK/STAT-driven gastrointestinal diseases.
Assuntos
Artrite Reumatoide , Doenças Inflamatórias Intestinais , Inibidores de Janus Quinases , Humanos , Inibidores de Janus Quinases/efeitos adversos , Voluntários Saudáveis , Artrite Reumatoide/tratamento farmacológico , Jejum , Doenças Inflamatórias Intestinais/tratamento farmacológicoRESUMO
Ractopamine (RAC) is universally known for improving lean meat percentage in livestock and thus is widely introduced as a feed additive. However, it is difficult to eliminate the RAC residue in animal tissues from the biological system and will inevitably harm human health. Hence, detecting RAC molecules in biological samples is extremely significant. Herein, a novel strategy of supramolecular recognition-enhanced electrochemical sensing is presented. This platform was constructed by coupling ß-cyclodextrin (ß-CD) with palladium nanoparticles (Pd NPs)-functionalized three-dimensional reduced graphene oxide (3D-rGO) to form a nanocomposite (3D-rGO/Pd/ß-CD), which was further used to modify a glassy carbon electrode (GCE) for RAC detection. Benefiting from the attractive electrical conductivity and catalytic activity of 3D-rGO/Pd, as well as the unique small-molecule-recognition ability of ß-CD demonstrated by 1H NMR spectrum, which revealed the 1 : 2 binding mode of RAC with ß-CD, increased peak current signals of RAC were observed in the cyclic voltammetry (CV) test. Under optimized conditions, the wide linear concentration range spanned 1-95 µM, along with a relatively low detection limit of 0.12 µM (S/N = 3), as evidenced by the differential pulse voltammetry (DPV) approach. The platform also exhibited satisfactory stability and fine reproducibility, as well as high selectivity and good anti-interference capability. Moreover, this as-obtained sensor was efficiently applied in pork samples with a high recovery rate (96.44-103.99%), which provides a promising view of its electrochemical biosensing ability in practical applications.
Assuntos
Nanopartículas Metálicas , Nanocompostos , beta-Ciclodextrinas , Animais , Humanos , Carbono/química , Nanopartículas Metálicas/química , Reprodutibilidade dos Testes , Técnicas Eletroquímicas/métodos , Paládio/química , Eletrodos , Nanocompostos/químicaRESUMO
BACKGROUND: Cusatuzumab, a high-affinity anti-CD70 antibody, has shown preliminary activity as a treatment for acute myeloid leukaemia when combined with azacitidine. We aimed to determine the optimum dose for future trials of cusatuzumab in combination with azacitidine in patients with previously untreated acute myeloid leukaemia who are not eligible for intensive chemotherapy. METHODS: In this randomised, phase 2, open-label, dose-optimisation study we enrolled adult patients aged 18 years or older with newly diagnosed acute myeloid leukaemia not eligible for intensive chemotherapy, and with Eastern Cooperative Oncology Group scores of 0-2, from 40 hospitals and centres across seven countries. In part one of the trial, participants were randomly allocated 1:1 to 10 mg/kg or 20 mg/kg intravenous cusatuzumab on days 3 and 17, combined with subcutaneous or intravenous azacitidine 75 mg/m2 on days 1-7 in 28-day cycles. The primary efficacy outcome was the rate of complete remission in the intention-to-treat group. The two dose cohorts were evaluated independently without between-cohort statistical comparison. Safety analyses were performed in all patients who received one dose of study drug. Part two of the trial was planned to be a single-arm expansion to evaluate cusatuzumab plus azacitidine at the cusatuzumab dose level selected in part one (primary hypothesis ≥35% rate of complete remission vs null hypothesis of 20%); however, changes in the acute myeloid leukaemia treatment landscape during this trial made it unlikely that enrolment to part two of the study would be clinically feasible, so the study stopped at the end of part one. The trial was registered at ClinicalTrials.gov, NCT04023526. FINDINGS: 103 patients were enrolled between Aug 30, 2019, and Feb 25, 2020, and randomly assigned to either cusatuzumab 10 mg/kg (n=51) or 20 mg/kg (n=52). Median follow-up was 7·2 months (IQR 10·7 months). 57 of 103 (55%) patients were male and 46 (45%) patients were female, 78 (76%) were White, one (1%) was Asian, and 24 (23%) did not report their race. In the 10 mg/kg group, complete remission rate was 12% (six of 51 patients; 95% CI 6-23) and in the 20 mg/kg group was 27% (14 of 52; 17-40). Grade 3 or worse treatment-emergent adverse events (TEAEs) were similar between the cusatuzumab 10 mg/kg (n=51) and 20 mg/kg (n=51) cohorts and included thrombocytopenia (24 patients [47%] vs 29 [57%]), anaemia (24 [47%] vs 17 [33%]), and neutropenia (20 [39%] in both cohorts). Serious TEAEs were also similar in the two cohorts (44 [86%] vs 40 [78%]). Treatment-related TEAEs leading to death were reported in both groups (three patients [6%] in the 10 mg/kg group vs one patient [2%] in the 20 mg/kg group); the reported causes of death were pneumonia (n=2) and septic shock (n=2). INTERPRETATION: Although part one of this study was not designed to formally compare the two dose cohorts for efficacy, the totality of clinical data for cusatuzumab studies performed to date indicate that cusatuzumab 20 mg/kg plus azacitidine represents the optimal dose for further studies. A phase 1b study investigating the triple combination of cusatuzumab with venetoclax and azacitidine is underway (NCT04150887). FUNDING: Janssen Research & Development and argenx.
Assuntos
Antineoplásicos , Leucemia Mieloide Aguda , Adulto , Humanos , Masculino , Feminino , Azacitidina/efeitos adversos , Antineoplásicos/uso terapêutico , Leucemia Mieloide Aguda/diagnóstico , Indução de Remissão , Esquema de Medicação , Anticorpos Monoclonais/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversosRESUMO
A series of microwave biochars derived from wheat straw in the presence of a granulated activated carbon (GAC) catalyst, using a range of microwave conditions, were produced, characterized and tested as sorbents of three benzene series volatile organic compounds (VOCs). The microwave biochar with the greatest specific surface area (SSA), total pore volume (TPV), and micropore volume (312.62â¯m2â¯g-1, 0.2218â¯cm3â¯g-1, and 0.1380â¯cm3â¯g-1, respectively), were produced with 1:3 biomass:GAC catalyst mass ratio, 10â¯min microwave irradiation time, and at 500â¯W power level (WB500). Maximum adsorption capacities of WB500 to benzene, toluene and o-xylene were 53.9â¯mgâ¯g-1, 75.8â¯mgâ¯g-1 and 63.0â¯mgâ¯g-1, respectively, and were directly correlated to microwave biochar properties such as SSA, TPV or micropore volume, but were also influenced by VOC properties such as molecular polarity and boiling point. Kinetic modeling suggested that adsorption was governed by both physical partitioning and chemisorption mechanisms. In addition, microwave biochars maintained 79% to 92% of their initial adsorption capacity after ten adsorption/desorption cycles. These results suggest that microwave biochars produced with an GAC catalyst have excellent potential for efficient use in the removal of VOCs from waste gas.
Assuntos
Carvão Vegetal , Compostos Orgânicos Voláteis , Adsorção , Benzeno , Micro-OndasRESUMO
Improving the adsorption ability of layered double hydroxide (LDH) has been considered as a promising strategy to promote its photodegradation of aqueous pollutants. In this work, nickel-aluminium layered double hydroxides (NiAl-LDH)/biochar nanocomposites were prepared using a simple coprecipitation method, and then applied in synergistic adsorption-photodegradation of tetracycline (TC) in aqueous solutions. In addition, the governing TC removal mechanisms by the nanocomposites were revealed. All NiAl-LDH/BC samples showed strong adsorption and photodegradation of TC. The Langmuir maximum TC adsorption capacity of optimized NiAl-LDH/BC-0.5 reached 124.2 mg/g, which was much better than that of NiAl-LDH (56.1 mg/g) and biochar (11.1 mg/g). Besides, TC photodegradation rate constant of NiAl/BC-0.5 was 3.6 and 4.4 times of that of NiAl-LDH and BC, respectively. The NiAl/BC-0.5 exhibited the maximum TC adsorption-photodegradation efficiency 94.4% in 90 min compared to NiAl-LDH (73.7%) and BC (48.2%). The rate constant of modified Elovich kinetic model for synergistic adsorption and photodegradation on NiAl/BC-0.5 (9.477 min-1) was the highest among the composites. The NiAl-LDH/BC had significantly larger BET surface areas than NiAl-LDH and BC. The step scheme (S-scheme) heterostructures were constructed on the interface of BC and NiAl-LDH in nanocomposites, which facilitated the transfer of photo-induced charges. This work demonstrates that combination of NiAl-LDH and biochar can create synergy for TC adsorption-photodegradation, which is a promising and green strategy.
Assuntos
Alumínio , Poluentes Químicos da Água , Adsorção , Alumínio/química , Níquel/química , Poluentes Químicos da Água/química , Fotólise , Hidróxidos/química , Tetraciclina , Hidróxido de Alumínio/química , AntibacterianosRESUMO
BACKGROUND: Teclistamab (JNJ-64007957), a B-cell maturation antigen × CD3 bispecific antibody, displayed potent T-cell-mediated cytotoxicity of multiple myeloma cells in preclinical studies. OBJECTIVE: A first-in-human, Phase I, dose escalation study (MajesTEC-1) is evaluating teclistamab in patients with relapsed/refractory multiple myeloma. PATIENTS AND METHODS: To estimate the efficacious therapeutic dosing range of teclistamab, pharmacokinetic (PK) data following the first cycle doses in the low-dose cohorts in the Phase I study were modeled using a 2-compartment model and simulated to predict the doses that would have average and trough serum teclistamab concentrations in the expected therapeutic range (between EC50 and EC90 values from an ex vivo cytotoxicity assay). RESULTS: The doses predicted to have average serum concentrations between the EC50 and EC90 range were validated. In addition, simulations showed that weekly intravenous and subcutaneous doses of 0.70 mg/kg and 0.72 mg/kg, respectively, resulted in mean trough levels comparable to the maximum EC90. The most active doses in the Phase I study were weekly intravenous doses of 0.27 and 0.72 mg/kg and weekly subcutaneous doses of 0.72 and 1.5 mg/kg, with the weekly 1.5 mg/kg subcutaneous doses selected as the recommended Phase II dose (RP2D). With active doses, exposure was maintained above the mean EC90. All patients who responded to the RP2D of teclistamab had exposure above the maximum EC90 in both serum and bone marrow on cycle 3, Day 1 of treatment. CONCLUSIONS: Our findings show that PK simulations of early clinical data together with ex vivo cytotoxicity estimates can inform the identification of a bispecific antibody's therapeutic range. CLINICAL TRIAL REGISTRATION: NCT03145181, date of registration: May 9, 2017.
Assuntos
Antineoplásicos , Mieloma Múltiplo , Administração Intravenosa , Antineoplásicos/uso terapêutico , Antígeno de Maturação de Linfócitos B , Humanos , Mieloma Múltiplo/tratamento farmacológicoRESUMO
The two main objectives of this analysis were to (i) characterize the relationship between immunoglobulin (Ig) exposure and chronic inflammatory demyelinating polyneuropathy (CIDP) disease severity using data from 171 patients with CIDP who received either subcutaneous Ig (IgPro20; Hizentra® ) or placebo (PATH study), and to (ii) simulate and compare exposure coverage with various dosing approaches considering weekly dosing to be the reference dose. IgG pharmacokinetic (PK) parameters, including those from a previous population PK model, were used to predict individual IgG profile and exposure metrics. Treatment-related changes in Inflammatory Neuropathy Cause and Treatment (INCAT) scores were best described by a maximum effect (Emax ) model as a function of ΔIgG (total serum IgG at INCAT score assessment minus baseline IgG levels before intravenous Ig restabilization). Simulations indicate that flexible dosing from daily to biweekly (every other week) provide an exposure coverage equivalent to that of a weekly Ig dose.
Assuntos
Imunoglobulina G/administração & dosagem , Fatores Imunológicos/administração & dosagem , Modelos Biológicos , Polirradiculoneuropatia Desmielinizante Inflamatória Crônica/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Esquema de Medicação , Feminino , Humanos , Imunoglobulina G/metabolismo , Fatores Imunológicos/farmacocinética , Injeções Subcutâneas , Masculino , Pessoa de Meia-Idade , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento , Adulto JovemRESUMO
A multifunctional targeted drug delivery platform (CDHAâ»MGO) has been successfully constructed by grafting ß-cyclodextrinâ»hyaluronic acid polymers (CDHA) to Fe3O4â»graphene oxide (MGO). The obtained CDHAâ»MGO nanocomposite has good water-dispersibility, easy magnetic separation, high near-infrared (NIR) photothermal heating, and excellent biocompatibility. The ß-cyclodextrin-hyaluronic acid polymers efficaciously enhance the doxorubicin (DOX) loading amount up to 485.43 mg·g-1. Meanwhile, the Fe3O4â»graphene oxide provides a facile photothermal response mechanism to handle the NIR-triggered release of DOX in weak acidic solvent environments. Significantly, the DOX-loaded nanocomposite (DOX@CDHAâ»MGO) has displayed CD44 receptor-mediated active targeting recognition and chemo-photothermal synergistic therapy of hepatoma cells. These findings suggest that the as-prepared drug delivery platform would be of valuable potential for cancer-targeted photo-chemotherapy.
RESUMO
High throughput in vitro microsomal stability assays are widely used in drug discovery as an indicator for in vivo stability, which affects pharmacokinetics. This is based on in-depth research involving a limited number of model drug-like compounds that are cleared predominantly by cytochrome P450 metabolism. However, drug discovery compounds are often not drug-like, are assessed with high throughput assays, and have many potential uncharacterized in vivo clearance mechanisms. Therefore, it is important to determine the correlation between high throughput in vitro microsomal stability data and abbreviated discovery in vivo pharmacokinetics study data for a set of drug discovery compounds in order to have evidence for how the in vitro assay can be reliably applied by discovery teams for making critical decisions. In this study the relationship between in vitro single time point high throughput microsomal stability and in vivo clearance from abbreviated drug discovery pharmacokinetics studies was examined using 306 real world drug discovery compounds. The results showed that in vitro Phase I microsomal stability t(1/2) is significantly correlated to in vivo clearance with a p-value<0.001. For compounds with low in vitro rat microsomal stability (t(1/2)<15 min), 87% showed high clearance in vivo (CL>25 mL/min/kg). This demonstrates that high throughput microsomal stability data are very effective in identifying compounds with significant clearance liabilities in vivo. For compounds with high in vitro rat microsomal stability (t(1/2)>15 min), no significant differentiation was observed between high and low clearance compounds. This is likely owing to other clearance pathways, in addition to cytochrome P450 metabolism that enhances in vivo clearance. This finding supports the strategy used by medicinal chemists and drug discovery teams of applying the in vitro data to triage compounds for in vivo PK and efficacy studies and guide structural modification to improve metabolic stability. When in vitro and in vivo data are both available for a compound, potential in vivo clearance pathways can be diagnosed to guide further discovery studies.
Assuntos
Microssomos/efeitos dos fármacos , Microssomos/metabolismo , Animais , Avaliação Pré-Clínica de Medicamentos , Masculino , Preparações Farmacêuticas/sangue , Ratos , Ratos Sprague-DawleyRESUMO
AIM: A UHPLC-MS/MS assay was developed to quantify urinary dehydroepiandrosterone (DHEA), 7ß-hydroxy-DHEA, cortisone and 6ß-hydroxycortisone as potential biomarkers to predict CYP3A activity. RESULTS: A sensitive assay at LLOQ of 0.500 ng/ml with good accuracy and precision was developed for the four analytes in human urine. This UHPLC-MS/MS assay was optimized by eliminating nonspecific loss of the analytes in urine, ensuring complete hydrolysis of the conjugates to unconjugated forms and use of the product ions of [M+H-H2O]+ for multiple reaction monitoring detection of DHEA and 7ß-hydroxy-DHEA. CONCLUSION: This assay was successfully applied to a pilot clinical study. It is also suitable for future drug-drug interaction studies to continue evaluating the potential of these steroids as biomarkers for CYP3A inhibition and induction.
Assuntos
Biomarcadores/urina , Cortisona/urina , Citocromo P-450 CYP3A/metabolismo , Desidroepiandrosterona/urina , Espectrometria de Massas em Tandem , Urinálise/métodos , Cromatografia Líquida de Alta Pressão/normas , Cortisona/metabolismo , Cortisona/normas , Citocromo P-450 CYP3A/química , Desidroepiandrosterona/metabolismo , Desidroepiandrosterona/normas , Interações Medicamentosas , Humanos , Hidroxilação , Limite de Detecção , Extração Líquido-Líquido , Controle de Qualidade , Espectrometria de Massas em Tandem/normas , Urinálise/instrumentaçãoRESUMO
Speciation can fundamentally affect on the stability and toxicity of heavy metals in sludge from wastewater treatment plants. This research investigated the speciation of heavy metals in sludge from both municipal and industrial sources, and metal speciation change as a result of drying process to reduce sludge volume. The changes in sludge properties including sludge moisture content, temperature, density, and electrical conductivity were also monitored to provide insights into the mechanisms causing the change in heavy metal speciation. The results show that the drying process generally stabilized Cr, Cu, Cd, and Pb in sludge by transforming acid-soluble, reducible, and oxidizable species into structurally stable forms. Such transformation and stabilization occurred regardless of the sludge source and type, and were primarily caused by the changes in sludge properties associated with decomposition of organic matter and sulfide. The results enhanced our understanding of the geochemical behavior of heavy metals in municipal sludge, and are useful for designing a treatment system for environment-friendly disposal of sludge.
Assuntos
Metais Pesados/química , Esgotos/química , Poluentes Químicos da Água/química , Dessecação , Condutividade Elétrica , Metais Pesados/análise , Temperatura , Água/análise , Água/química , Poluentes Químicos da Água/análiseRESUMO
Antagonism of the chemokine receptor CXCR2 inhibits neutrophil trafficking and may thus be therapeutic in patients with chronic obstructive pulmonary disease and other lung disorders in which there is substantial infiltration by neutrophils. Here, we report the findings from a randomized, placebo-controlled, double-blind clinical trial of the small-molecule CXCR2 antagonist MK-7123 (formerly SCH 527123) that evaluated potential downstream effects of CXCR2 antagonism on immunogenic competency (B cell antibody response) in the adaptive immune system and delayed-type hypersensitivity (DTH) in healthy subjects (ages 34-65 years) dosed once daily for 30 days either with 30 mg MK-7123 (n=24) or placebo (n=7). Eligible subjects were seronegative for anti-hepatitis A virus (HAV) immunoglobulin G (IgG) and positive for DTH response to intradermal injection of Candida albicans antigen at screening. Subjects were vaccinated for HAV on treatment Day 2. The primary endpoints were anti-HAV IgG titer on Day 30 and DTH response magnitude on Day 27. Pharmacokinetic and safety endpoints were also assessed. We observed that anti-HAV IgG titers and DTH responses did not differ significantly between MK-7123-treated and placebo-treated subjects. Twenty-eight days postvaccination, seroconversion (anti-HAV IgG titer≥10mIU/mL) was observed in 87.5% and 85.7% of MK-7123-treated and placebo-treated subjects, respectively; mean (±SE) titers were 27.3±5.5 and 21.4±4.3mIU/mL, respectively. Treatment with MK-7123 was generally well tolerated. Doses were followed by temporary reductions in absolute peripheral blood neutrophil count. In conclusion, this study found that B cell response and cell-mediated immunity were not altered by CXCR2 antagonism with MK-7123.
Assuntos
Benzamidas/uso terapêutico , Ciclobutanos/uso terapêutico , Hipersensibilidade Tardia/tratamento farmacológico , Neutrófilos/imunologia , Doença Pulmonar Obstrutiva Crônica/imunologia , Receptores de Interleucina-8B/antagonistas & inibidores , Adulto , Idoso , Formação de Anticorpos/efeitos dos fármacos , Benzamidas/efeitos adversos , Contagem de Células , Células Cultivadas , Ciclobutanos/efeitos adversos , Feminino , Anticorpos Anti-Hepatite A/sangue , Humanos , Imunidade Celular/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Neutrófilos/efeitos dos fármacos , VacinaçãoRESUMO
To clarify the contribution of different component of selenium is the basis for evaluation of the sustainable development and utilization of selenium-rich soil. Xiuzhou district, where the soil is rich in selenium, was chosen as the study area, and its soil selenium content was qualitatively separated as the natural background component and the exogenous component through cross-validation of integrated geo-analysis and multivariate statistics. Subsequently, the contribution rate of the different component of the selenium content was separated quantitatively using frequency distribution functions. The results showed that the natural background component accounted for 90% in the soil selenium content and the exogenous component accounted for 10%, which indicated that the land sources rich in selenium in Xiuzhou district has the potential for sustainable development and utilization.
Assuntos
Selênio/análise , Solo/química , China , GeografiaRESUMO
Three different weight grades of sludge granules (2.5, 5, 10 g) were dried at constant temperature of 100, 200, 300, 400 and 500 degrees C, respectively. Then characteristics of weight loss and change of apparent form during sludge drying were analyzed. Results showed that there were three stages during sludge drying at 100-200 degrees C: acceleration phase, constant-rate phase, and falling-rate phase. At 300-500 degrees C, there were no constant-rate phase, but due to lots of cracks generated at sludge surface, average drying rates were still high. There was a quadratic nonlinear relationship between average drying rate and drying temperature. At 100-200 degrees C, drying processes of different weight grade sludge granules were similar. At 300-500 degrees C, drying processes of same weight grade of sludge granules were similar. Little organic matter decomposed till sludge burning at 100-300 degrees C, while some organic matter began to decompose at the beginning of sludge drying at 400-500 degrees C.